Back
 AiM  Vol.8 No.11 , November 2018
Prevalence and Antimicrobial Susceptibility Profile of Metallo-β-Lactamase Producing Pseudomonas aeruginosa Isolates at Kenyatta National Hospital
Abstract: Pseudomonas aeruginosa is a major cause of nosocomial infections with high mortality rates. The organism is highly resistant to most classes of drugs used and can develop resistance during treatment. One of the resistance mechanisms of P. aeruginosais is Metallo-β-Lactamase (MBL) production. MBL producing P. aeruginosa is a major health concern given it’s resistance to almost all available drugs. The prevalence of this resistant strain is unknown since there is no standardized method for testing MBL production. This was a laboratory based cross-sectional prospective study that was carried out from September 2015 to March 2016 at Kenyatta National Hospital. Ninety-nine isolates of P. aeruginosa were collected during the period and tested for antimicrobial susceptibility and isolates found to be resistant to imipenem tested for MBL production. The results indicated high resistance of P. aeruginosa to commonly used drugs. Of the isolates tested 69.7% were resistant to piperacillin, 63.6% were resistant to aztreonam, 58.6% were resistant to levofloxacin, 55.6% were resistant to cefipime, 65.7% were resistant to ceftazidime, 68.7% were resistant to ticarcillin-clavulanate, 72.2% were resistant to meropenem, 64.9% were resistance to imipenem while 86.4% of urine isolates were resistant to ofloxacin. Of the isolates resistant to imipenem 87.3% were found to be MBL producers. In conclusion, P. aeruginosais highly resistant to the drugs currently is used for treatment and resistance to carbapenems is largely due to MBL production.
Cite this paper: Karuitha, J. , Akinyi, O. , Njeri, M. and Marianne, M. (2018) Prevalence and Antimicrobial Susceptibility Profile of Metallo-β-Lactamase Producing Pseudomonas aeruginosa Isolates at Kenyatta National Hospital. Advances in Microbiology, 8, 885-893. doi: 10.4236/aim.2018.811059.
References

[1]   Microbiology and Immunology Online.
http://www.microbiologybook.org/

[2]   Vahdani, M., Azimi, L., Asgzari, B., Bazmi, F. and Lari, R. (2012) Phenotypic Screening of Extended Spectrum Betalactamases and Metallo-β-Lactamase in Multi Drug Resistant Pseudomonas aeruginosa from Infection Burns. Annals of Burns and Fire Disasters, 25, 78-82

[3]   Wirth, W.F., Picoli, U.S., Cantarelli, V.V., Goncalves, A.L., Brust, F.R., Santos, L.M. and Barreto, M.F. (2009) Metallo-β-Lactamase-Producing Pseudomonas aeruginosa in Two Hospitals from Southern Brazil. Brazilian Journal of Infectious Diseases, 13, 170-172.
https://doi.org/10.1590/S1413-86702009000300003

[4]   Lambert, L.M., Savey, S.C., Palomar, M., Hiesmayr, M., Morales, I., Agodi, A., Frank, U., Mertens, K., Schumacher, M. and Wolkewitz, M. (2011) Clinical Outcome of Health Care Associated Infections and Antimicrobial Resistance in Patients Admitted European Intensive Care Units: A Cohort Study. The Lancet Infectious Diseases, 11, 30-38.
https://doi.org/10.1016/S1473-3099(10)70258-9

[5]   Pfaller, M.A. (2012) Medical Microbiology. 7th Edition, Saunders, Philadelphia.

[6]   Neda, G., Scott, A., Andrew, P. and Nader, P. (2009) Detection of Point Mutations Associated with Antibiotic Resistance in Pseudomonas aeruginosa. International Journal of Antimicrobial Agents, 34, 414-418.
https://doi.org/10.1016/j.ijantimicag.2009.05.013

[7]   McGowan, J.E. (2006) Resistance in Non-Fermenting Gram-Negative Bacteria: Multidrug Resistance to the Maximum. American Journal of Infection Control, 34, S29-S37.
https://doi.org/10.1016/j.ajic.2006.05.226

[8]   Hancock, R.E. and Speert, D.P. (2000) Antibiotic Resistance in Pseudomonas aeruginosa: Mechanisms and Impact on Treatment. Drug Resistance Updates, 3, 247-255.
https://doi.org/10.1054/drup.2000.0152

[9]   Gooderham, W.J. and Hancock, R.E.W. (2009) Regulation of Virulence and Antibiotic Resistance by Two Component Regulatory System in Pseudomonas aeruginosa. FEMS Microbiology Reviews, 33, 279-294.
https://doi.org/10.1111/j.1574-6976.2008.00135.x

[10]   Zhao, W.H. and Hu, Z.Q. (2010) Betalactamases Identified in Clinical Isolates of Pseudomonas aeruginosa. Critical Reviews in Microbiology, 36, 245-258.
https://doi.org/10.3109/1040841X.2010.481763

[11]   Wang, J., Zhao, Y.J., Qu, T.T., Shen, P., Wei, Z.Q., Yu, Y.S. and Li, L.J. (2010) Molecular Epidemiology and Mechanism of Carbepenem Resistance in Pseudomonas aeruginosa Isolates from Chinese Hospitals. International Journal of Antimicrobial Agents, 35, 486-491.
https://doi.org/10.1016/j.ijantimicag.2009.12.014

[12]   Poirel, L., Pitout, J.D. and Nordmann, P. (2007) Carbapenemases: Molecular Diversity and Clinical Consequences. Future Microbiology, 2, 501-512.
https://doi.org/10.2217/17460913.2.5.501

[13]   National Committee for Clinical Laboratory Standards (2015) Performance Standards for Antimicrobial Susceptibility Testing: Twenty Third Informational Supplement. M100-S23, NCCLS, Wayne, PA.

[14]   Yong, D., Lee, K., Yum, J.H., Shin, H.B., Rossolini, G.M. and Chong, Y. (2002) Imipenem-EDTA Disk Method for Differentiation of Metallo-β-Lactamase-Producing Clinical Isolates of Pseudomonas spp. and Acinetobacter spp. Journal of Clinical Microbiology, 40, 3798-3801.
https://doi.org/10.1128/JCM.40.10.3798-3801.2002

[15]   Hanberger, H., Garcia-Rodriguez, J.A., Gobernado, M., Goossens, H., Nilsson, L.E. and Struelens, L.J. (1999) Antibiotic Susceptibility among Aerobic Gram-Negative Bacilli in Intensive Care Units in 5 European Countries. French and Portuguese ICU Study Groups. JAMA, 281, 67-71

[16]   Pitout, J.D., Revathi, G., Chow, B.L. and Laurent, P. (2008) Metallo-β-Lactamase Producing Pseudomonas aeruginosa Isolated from a Large Tertiary Center in Kenya. Clinical Microbiology and Infection, 14, 755-759.
https://doi.org/10.1111/j.1469-0691.2008.02030.x

[17]   Galvani, A.A. and Tukmechi, T. (2015) Determination of the Prevalence of Metallo-β-Lactamase Producing Pseudomonas aeruginosa Strains from Clinical Samples by Imipenem-Edta Combination Disk Method in Mottahari and Emam Khomaini Hospitals of Urmia. Report of Health Care, 1, 65-68.

[18]   Hammami, S., Boutiba-Ben, B., Ghozzi, R., Saidani, M., Amine, S. and Ben, S. (2011) Nosocomial Outbreak of Imipenem-Resistant Pseudomonas aeruginosa Producing VIM-2 Metallo-β-Lactamase in a Kidney Transplantation Unit. Diagonostic Pathology, 6, 106.
https://doi.org/10.1186/1746-1596-6-106

[19]   Livermore, D.M. (2001) Of Pseudomonas, Porins, Pumps and Carbapenems. Journal of Antimicrobial Chemotherapy, 47, 247-250.
https://doi.org/10.1093/jac/47.3.247

[20]   Quale, J., Bratu, S., Gupta, J. and Landman, D. (2006) Interplay of Efflux System, ampC and oprD Expression in Carbapenem Resistance of Pseudomonas aeruginosa Clinical Isolates. Antimicrobial Agents and Chemotherapy, 50, 1633-1641.
https://doi.org/10.1128/AAC.50.5.1633-1641.2006

[21]   Rodriguez-Martinez, J.M., Poirel, L. and Nordmann, P. (2009) Molecular Epidemiology and Mechanisms of Carbapenem Resistance. Antimicrobial Agents and Chemotherapy, 53, 4783-4788.
https://doi.org/10.1128/AAC.00574-09

[22]   Trias, J. and Nikaido, H. (1990) Outer Membrane Protein D2 Catalyzes Facilitated Diffusion of Carbapenems and Penems through the Outer Membrane of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 34, 52-57.
https://doi.org/10.1128/AAC.34.1.52

[23]   Bahar, M.A., Jamali, S. and Samadikuchaksaraei, A. (2010) Imipenem-Resistant Pseudomonas aeruginosa Strains Carry Metallo-β-Lactamase Gene blaVIM in a Level 1 Iranian Burn Hospital. Burns, 36, 826-830.
https://doi.org/10.1016/j.burns.2009.10.011

[24]   Livermore, D.M. (1992) Interplay of Impermeability and Chromosomal β-Lactamase Activity in Imipenem-Resistant Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 36, 2046-2048.
https://doi.org/10.1128/AAC.36.9.2046

 
 
Top